What the new the Netherlands guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
May 2025 — Vol. 2, No. 5
Page 4 of 4 of this archive, newest first.
Also filed — page 4
the rolling newsroom, May 2025Inspectors cite Calder Vale Peptides of Skipton over sterility assurance
The observation that closes a facility is rarely the dramatic one.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
LEADER extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A shortage listing ends. 16 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The consolidator trading as Meridian Freight Partners enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
Independent analysis puts a KP liraglutide lot at 97.9%, against 97.0% on the certificate
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
SGN declines, for the 6th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The 29-day notice: how a compounding wind-down works in Norway
The document is four pages. Three of them are about dates.
KP declines, for the 24th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Norway health authority warns on falsified dulaglutide pens
Reported from the analysis, not from a warning notice.
A shortage listing ends. 10 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
What a 23% rise in coupling-reagent prices does to a 10 mg vial
Follow the resin, not the catalogue.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
From the floor in Hangzhou: 4 posters, one theme
Reported from the sessions, and from the two hours afterwards.
What the new the Netherlands guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
SURPASS-2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Nigeria health authority warns on falsified liraglutide pens
Reported from the analysis, not from a warning notice.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
A shortage listing ends. 4 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.